Nemesis Bioscience is a biopharmaceutical company developing DNA therapeutics administered before antibiotics to inactivate resistance in bacterial pathogens. It makes existing antibiotics work again, prevents the spread of resistance genes, and protects the efficacy of new antibiotics. The company leverages technology that can also be applied for the reduction of chemotherapeutic toxicity, inactivation of virulence factors, and in vivo synthesis of biofuels and therapeutics.